Drug may prevent the progression of high-grade PIN to prostate cancer

When prostate cells that line tiny sacs in the prostate and the ducts that carry fluid to the ejaculatory duct begin to look abnormal, pathologists render a diagnosis of prostatic intraepithelial neoplasia (PIN), classifying it as either high-grade or low-grade PIN. In high-grade PIN, the degree of cellular abnormality is more pronounced than in low-grade PIN, and studies have shown that high-grade PIN is more likely to progress to cancer.

In men with both prostate cancer and high-grade PIN, hormone therapy has markedly decreased the prevalence and extent of PIN. That got two Chinese researchers wondering: could a drug used for hormone therapy prevent the progression of high-grade PIN to cancer?

To find out, they followed 172 patients diagnosed with high-grade PIN but no evidence of prostate cancer for five years. Half took a small daily dose of flutamide for 12 months; the rest took a placebo. At the end of the study, 11.6% of the patients taking flutamide had developed prostate cancer compared with 30.2% of those taking a placebo, suggesting that a preventive dose of flutamide can keep high-grade PIN in check.

SOURCE: Zhao Z, Shen W. Flutamide Reduced Prostate Cancer Development and Prostate Stem Cell Antigen mRNA Expression in High-Grade Prostatic Intraepithelial Neoplasia. International Journal of Cancer 2007;122:864–70. PMID: 17957793.

Originally published April 1, 2008; Last reviewed April 18, 2011

Comments
1
Donald Mullis

12 years ago a biopsy of my prostate showed PIN. 6 weeks later a repeat biopsy was normal. I have take Proscar for the last 12 years. My PSA has stayed around 2.17. The Urologist now 12 years later wants to do another biopsy. My prostate exam is normal. I am 70 years old and possibly have had two heart attacks. I feel a biopsy at this time is too aggressive. What is the latest thinking about how to proceed.

Post a Comment

This blog aims to provide reliable information as well as healthy dialog about the topics covered. We reserve the right to remove comments for any reason, particularly those that do not relate directly to the contents of this post, are commercial in nature, contain objectionable or inappropriate material, or otherwise violate our Privacy Policy. Comments on this blog do not represent the views of our editors or Harvard University, and have not been checked for accuracy. All comments submitted to this site become the non-exclusive property of Harvard University.